 <h1>Linagliptin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>More frequently reported side effects include:</b> hypoglycemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to linagliptin: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, linagliptin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking linagliptin:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>increased hunger</li>
<li>loss of consciousness</li>
<li>nausea</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>constipation</li>
<li>cough</li>
<li>fever</li>
<li>hives, welts, itching, or skin rash</li>
<li>large, hard skin blisters</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the skin</li>
<li>severe joint pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of linagliptin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Muscle aches</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to linagliptin: oral tablet</i></p><h3>Gastrointestinal</h3><p>During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea).  Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin.  Postmarketing reports of acute pancreatitis, including fatalities, have been received.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Constipation, increased amylase levels</p>
<p><b>Frequency not reported</b>: Pancreatitis</p>
<p><b>Postmarketing reports</b>: Acute pancreatitis<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse event reported was nasopharyngitis.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Drug hypersensitivity</p>
<p><b>Postmarketing reports</b>: Serious hypersensitivity reactions<sup>[Ref]</sup></p><p>Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with this drug.  These reactions have occurred within the first 3 months, with some occurring after the first dose.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>The incidence of hypoglycemia in patients treated with this drug as monotherapy, or in combination with metformin or pioglitazone, was similar to the incidence observed in placebo-treated patients.  When given in combination with metformin plus a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo with metformin plus a sulfonylurea.  As add-on to stable insulin therapy, the incidence of hypoglycemia was similar to placebo (31.4% versus 32.9%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hypoglycemia, hypertriglyceridemia, hyperlipidemia, increased uric acid<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Rash, angioedema, urticaria</p>
<p></p>
<p>Dipeptidyl peptidase-4 inhibitors:</p>
<p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, extremity pain<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p></div>
<div class="more-resources" id="moreResources">
<h2>More about linagliptin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>59 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Linagliptin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tradjenta</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to linagliptin: oral tablet</i></p><h3>Gastrointestinal</h3><p>During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea).  Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin.  Postmarketing reports of acute pancreatitis, including fatalities, have been received.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Constipation, increased amylase levels</p><p><b>Frequency not reported</b>: Pancreatitis</p><p><b>Postmarketing reports</b>: Acute pancreatitis<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse event reported was nasopharyngitis.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Drug hypersensitivity</p><p><b>Postmarketing reports</b>: Serious hypersensitivity reactions<sup>[Ref]</sup></p><p>Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with this drug.  These reactions have occurred within the first 3 months, with some occurring after the first dose.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>The incidence of hypoglycemia in patients treated with this drug as monotherapy, or in combination with metformin or pioglitazone, was similar to the incidence observed in placebo-treated patients.  When given in combination with metformin plus a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo with metformin plus a sulfonylurea.  As add-on to stable insulin therapy, the incidence of hypoglycemia was similar to placebo (31.4% versus 32.9%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hypoglycemia, hypertriglyceridemia, hyperlipidemia, increased uric acid<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Rash, angioedema, urticaria</p><p></p><p>Dipeptidyl peptidase-4 inhibitors:</p><p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough, nasopharyngitis, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, extremity pain<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p><h2>More about linagliptin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>59 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Linagliptin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>